Overview

A Study of Oxytocin for the Treatment of Social Impairment in Individuals With High Functioning Autism Spectrum Disorder

Status:
Active, not recruiting

Trial end date:
2022-09-01

Target enrollment:

Participant gender:

Summary

This study is an 8-week pilot trial with oxytocin nasal spray (Syntocinon) as a treatment for social impairment in children and adults with high functioning autism spectrum disorders (ASD). The investigators hypothesize that oxytocin will be safe, tolerable, and effective in improving social deficits in individuals with ASD.

Phase:

Phase 3

Details

Lead Sponsor:

Massachusetts General Hospital

Treatments:

Oxytocin